home / stock / abcl / abcl articles
John Montalbano, Director at AbCellera Biologics (NASDAQ:ABCL), reported a large insider buy on November 8, according to a new SEC filing. What Ha...
Michael Hayden, Board Member at AbCellera Biologics (NASDAQ:ABCL), reported a large insider buy on September 26, according to a new SEC filing. Wh...
Benchmark analyst Robert Wasserman reiterated a Buy rating on AbCellera Biologics Inc. (NASDAQ: ABCL), lowering the price targe...
News, Short Squeeze, Breakout and More Instantly...
AbCellera Biologics Inc. Company Name:
ABCL Stock Symbol:
NASDAQ Market:
AbCellera Biologics Inc. Website:
AbCellera (Nasdaq: ABCL) will announce its second quarter 2024 financial results on Tuesday, August 6, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link t...
2024-06-13 05:40:00 ET Discovering new drugs can be a lucrative endeavor, but things aren't working out lately for AbCellera Biologics (NASDAQ: ABCL) . Shares of this unusual biotech stock are down by about 57% from the high water mark they set last summer. The steep losses migh...
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 12:20 p.m. Pacific Time (3:20 p.m. Eastern Time). A live audio webcast of the presentation may be accessed throug...